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Synthetic peptidomimetics may be designed to mimic functions of antimicrobial
peptides, including potentiation of antibiotics, yet possessing improved pharmacological
properties. Pairwise screening of 42 synthetic peptidomimetics combined with the
antibiotics azithromycin and rifampicin in multidrug-resistant (MDR) Escherichia coli
ST131 and Klebsiella pneumoniae ST258 led to identification of two subclasses of
α-peptide/β-peptoid hybrids that display synergy with azithromycin and rifampicin
(fractional inhibitory concentration indexes of 0.03–0.38). Further screening of the best
three peptidomimetics in combination with a panel of 21 additional antibiotics led to
identification of peptidomimetics that potentiated ticarcillin/clavulanate and erythromycin
against E. coli, and clindamycin against K. pneumoniae. The study of six peptidomimetics
was extended to Pseudomonas aeruginosa, confirming synergy with antibiotics for five
of them. The most promising compound, H-(Lys-βNPhe)8-NH2, exerted only a minor
effect on the viability of mammalian cells (EC50 ≥ 124–210µM), and thus exhibited
the highest selectivity toward bacteria. This compound also synergized with rifampicin
and azithromycin at sub-micromolar concentrations (0.25–0.5µM), thereby inducing
susceptibility to these antibiotics at clinically relevant concentrations in clinical MDR
isolates. This peptidomimetic lead and its analogs constitute promising candidates for
efficient repurposing of rifampicin and azithromycin against Gram-negative pathogens.
Keywords: peptidomimetic, antibiotic potentiation, multidrug resistance, synergy, Gram-negative, antibiotic
adjuvant
INTRODUCTION
Traditional antimicrobial therapies have become ineffective in treating infections caused by
multidrug-resistant (MDR) Gram-negative pathogens. Thus, new therapeutic strategies are
required tomanage these infections (Doi et al., 2017;WorldHealthOrganisation, 2017). Emergence
of resistance tomono-drug therapies has drawn attention to combination therapies with new agents
that limit resistance development or overcome resistance mechanisms (Kalan and Wright, 2011;
Brown, 2015; Ribeiro et al., 2015; Brown and Wright, 2016; Melander and Melander, 2017; Singh
et al., 2017; Moon and Huang, 2018). In this regard, co-application of certain peptides has been
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found to constitute a promising means for overcoming intrinsic
resistance to certain classes of antimicrobials (e.g., macrolides,
lincosamides and rifamycins) in Gram-negative pathogens due to
their ability to increase the permeability of the outer membrane
(Gill et al., 2015; Baker et al., 2018).
Despite the potential utility of peptides as potentiators
of antibiotics, their clinical use is hampered by unfavorable
pharmacological properties. In particular, many peptides also
affect the viability of mammalian cells and possess inherently
low stability toward proteolytic degradation, which (particularly
for linear peptides) represents a major obstacle for their
development into drugs (Ghosh and Haldar, 2015; Mojsoska
and Jenssen, 2015; Molchanova et al., 2017a). While most
naturally occurring peptides consist exclusively of α-amino
acid residues, peptidomimetics incorporate unnatural amino
acids or mimics thereof, resulting in alternative backbones
that resist enzymatic cleavage (Molchanova et al., 2017a). In
addition, end modifications (Jahnsen et al., 2015) may broaden
the chemical space covered. These features of peptidomimetics
enable design of compounds with fine-tuned physicochemical
properties that confer enhanced antibacterial activity as well
as an improved pharmacological profile (Méndez-Samperio,
2014). Moreover, certain peptidomimetics have proved capable
of potentiating traditional antibiotics (Renau et al., 2002;
Goldberg et al., 2013; Jammal et al., 2015; Lainson et al.,
2017), suggesting a possible role in combination therapy. Despite
displaying several features that are superior to those of peptides,
their therapeutic potential relies on technological advances to
enable reduced production cost, improved bioavailability, and
minimized toxicity toward host cells (Molchanova et al., 2017a).
Nonetheless, recent advances in synthesis of peptidomimetics
has enabled investigation of diverse compound arrays, thus
facilitating identification of peptidomimetic antibiotic adjuvants
with suitable pharmacological properties.
Benefiting from already available peptidomimetic arrays
(Hein-Kristensen et al., 2011; Jahnsen et al., 2012, 2014, 2015; Liu
et al., 2013), we performed a search for peptidomimetics capable
of circumventing the intrinsically low susceptibility to certain
antibiotics in Gram-negative pathogens. To address potential
toxicity issues, which are considered the most critical factor
currently limiting the therapeutic use of peptidomimetics, the
screening process was designed so that only compounds
that potentiate antibiotics at sub-micromolar nontoxic
concentrations were pursued. Thus, screening of pairwise
peptidomimetic-antibiotic combinations led to identification of
α-peptide/β-peptoid hybrids capable of inducing susceptibility
to azithromycin and rifampicin (below their putative clinical
breakpoints) in clinical MDR isolates of Escherichia coli, K.
pneumoniae and P. aeruginosa.
MATERIALS AND METHODS
Bacterial Strains, Antibiotics and Media
Bacterial strains used in this study comprise MDR clinical
isolates of E. coli ST131 (Cerquetti et al., 2010) and K.
pneumoniae ST258 (Jana et al., 2017), and American type
culture collection (ATCC) strains: ATCC 25922 (E. coli), ATCC
13883 (K. pneumoniae), and ATCC 27853 (P. aeruginosa).
Additional clinical isolates of E. coli, K. pneumoniae, and P.
aeruginosa resistant to β-lactams (including carbapenems and
cephalosporins) were provided by Laurent Poirel, Université
de Fribourg, Switzerland. The following growth media was
routinely used for bacterial culturing: Luria-Burtani (LB),
cation-adjusted Mueller-Hinton agar (MHA) and broth (MHB
II). All assays were performed in cation-adjusted MHA or
MHB II. Antibiotics were purchased from Sigma-Aldrich
and the peptidomimetic collection (Table S1) was curated
and provided by Henrik Franzyk. This collection contained
peptoids, α-peptide/β-peptoid hybrids, and a variety of end-
group modifications, thereby representing a wide range of
physicochemical and structural properties, including varied
cationic character, length and hydrophobicity. Stock solutions
were prepared by dissolving the compounds in deionized water,
while test solutions were obtained by further dilution with
MHB II medium.
Peptidomimetic Synthesis
α-Peptide/β-peptoid peptidomimetics were synthesized on a
Rink amide resin (loading: 0.5–0.7 mmol/g; 0.05–0.1 mmol
scale) in Teflon reactors (10mL) by standard Fmoc-based solid-
phase synthesis using the appropriate dimeric building blocks
(Bonke et al., 2008; Jahnsen et al., 2014). Fmoc deprotection was
performed with excess 20% piperidine in DMF (2 × 10min,
each time with 5mL; shaking at room temperature). After Fmoc
deprotection (and after coupling as well) the resin was washed
with DMF, MeOH, and DCM (each 3 × 3min with 5mL).
Coupling was performed with the appropriate building block
(2.0 equiv. for loading, 2.5 equiv for the first two elongations,
and 3.0 equiv. for subsequent elongations) and PyBOP/DIPEA
(1:2 equiv. relative to the building block) in DMF (2–3mL) for
>2 h under shaking at room temperature. Capping was applied
after the fourth coupling via treatment with Ac2O–DIPEA–
NMP 1:2:3 (5mL, 10min at room temperature). Final Fmoc
deprotection was followed by attachment of any N-terminal end
group: the carboxylic acid (5 equiv.) corresponding to the desired
moiety was added under conditions identical to those applied
for the above coupling procedure used for the dimeric building
blocks. Cleavage and simultaneous side chain deprotection:
Excess TFA-CH2Cl2 90:10 (2 × 30min under shaking at room
temperature). The filtrate was collected and the resin was eluted
with CH2Cl2 (2mL). The combined filtrates were concentrated
in vacuo, and co-evaporated three times with toluene. The
crude products were purified by using preparative HPLC, and
the resulting pure fractions were freeze-dried as previously
described (Jahnsen et al., 2012, 2015; Skovbakke et al., 2015;
Molchanova et al., 2017b).
Antimicrobial Susceptibility Testing
Minimal inhibitory concentrations (MICs) of peptidomimetics,
antibiotics and their combinations were determined by
broth microdilution according to the Clinical Laboratory
Standards Institute performance standards (Clinical and
Laboratory Standards Institute, 2013). Based on previous
studies indicating that among a range of tested antibiotics
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belonging to several classes azithromycin and rifampicin
displayed a high propensity to synergize with peptides, and
hence these antibiotics were chosen for the initial screening
of peptidomimetics to identify possible antibiotic adjuvants
(Jammal et al., 2015; Baker et al., 2016, 2018; Corbett et al.,
2017; Lyu et al., 2017; Wu et al., 2017; Domalaon et al.,
2018a,b; Yang et al., 2018). Here, a sub-MIC concentration
of 0.5µM peptidomimetic was tested in combination with
0.5µg/mL rifampicin or 1µg/mL azithromycin in 96-well
plates, followed by inoculum addition according to CLSI
guidelines. At these concentrations, control wells containing
either peptidomimetic or antibiotic individually did not inhibit
growth. Since rifampicin and azithromycin mainly are used to
treat infections with Gram-positive pathogens only CLSI clinical
breakpoints were available for such bacteria. Hence the clinically
relevant test concentrations were selected based on the CLSI
susceptibility breakpoints for Staphylococcus species (Clinical
and Laboratory Standards Institute, 2017): rifampicin (1µg/mL)
and azithromycin (2µg/mL). Potentiation of additional
antibiotics by peptidomimetics was determined by using
commercial 96-well plates containing varied concentrations of
standard antibiotics (COMPAN1F; Trek Diagnostic Systems
Inc.). The peptidomimetics were added immediately prior to
inoculation with pathogen, and then MICs were determined as
above. The MICs of peptidomimetic/antibiotic combinations
were determined according to the method above, and the
concentration ratios were selected based upon checkerboard
results with 2:1 and 1:4 ratio of peptidomimetic with
rifampicin or azithromycin, respectively. Minimal bactericidal
concentrations (MBCs) were determined by using growth-curve
assay plates. MIC plates were prepared as above, and then
the plates were incubated at 37◦C with continuous shaking.
Growth was recorded at 10min intervals as optical density
(OD) at 600 nm during 24 h. At 24 h, for wells without growth,
a sample was diluted 10-fold in sterile saline (0.9% sodium
chloride) and plated onto MHA, following CLSI guidelines
(Clinical and Laboratory Standards Institute, 1999).
Checkerboard Synergy Assay
The potential synergistic effects in peptidomimetic-antibiotic
combinations were assessed by using a two-dimensional
checkerboard assay (Garcia, 2010). Briefly, twofold dilutions
of peptide and antibiotic were prepared in MBH II media
along the X- and Y-axis, respectively, in 96-well plates. The
inoculum was added to the plates, and subsequently these were
incubated for 18–20 h. All steps for inoculum preparation and
broth microdilution were in accordance with the CLSI guidelines
(Clinical and Laboratory Standards Institute, 2013). The
fractional inhibitory concentration index (FICI) was calculated
as [MICA(A+B)/MICA(alone)] + [MICB(A+B)/MICB(alone)], where
MICA(A+B) represents the MIC of antibiotic (A) in combination
with peptidomimetic (B), while MICB(A+B) represents the
MIC of peptidomimetic (B) in combination with antibiotic
(A). MICA(alone) and MICB(alone) represent the MIC of each
compound individually. FICI values of ≤0.5 were interpreted
as synergy.
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TABLE 2 | Peptidomimetics studied: sequence, cytotoxicity, and MIC in clinical isolates of E. coli, K. pneumoniae and P. aeruginosa.
Cytotoxicity (µM) MIC (µM) and Selectivity Index (SId; in brackets)
No. Compound MW
(g/mol)
Charge Length
(residues)
NIH 3T3
EC50 ± SD
HepG2
EC50 ± SD
E. coli
ST131
K. pneumoniae
ST258
P. aeruginosa
ATCC 27853
Subclass I
1 H-(Lys-βNPhe)8-NH2 3470.44 +9 16 210.60 ± 26.78 123.97 ± 0.81 2 (84) 16 (10) 1 (167)
14 Ac-(Lys-βNPhe)6-NH2 2478.44 +6 12 323.50 ± 45.78 233.53 ± 7.95 4 (70) 64 (4) 16 (17)
15 Ac-(Lys-βNPhe)8-NH2 3286.24 +8 16 216.57 ± 23.12 121.37 ± 0.06 1 (169) 32 (5) 1 (169)
Subclass II
25 NDaba-Lys-βNspe-hArg-βNspe)3-NH2 2975.85 +8 13 166.90 ± 5.53 85.01 ± 3.06 2 (63) 8 (16) 8 (63)
26 [Spermine-Ac]b-(Lys-βNspe-hArg-
βNspe)3-NH2
3346.14 +10 13 53.20 ± 2.94 59.62 ± 0.71 1 (56) 8 (7) 2 (28)
28 TODAc-(Lys-βNspe-hArg-βNspe)3-NH2 2807.85 +6 13 217.57 ± 18.05 118.23 ± 2.05 2 (84) 16 (10) 16 (10)
aNDab, H2NCH2CH2NHCH2(C = O).
bSpermine-Ac, H2N(CH2)3NH(CH2)4NH(CH2)3NHCH2(C = O).
cTODA, H3CO(CH2)2O(CH2)2O(CH2)(C = O).
dSI was calculated as the average of the EC50 values for HepG2 and NIH 3T3 cells divided by the MIC.
Determination of Cell Viability and
Selectivity Indexes for Peptidomimetics
NIH 3T3 and HepG2 cells (both from ATCC, Manassas, VA,
USA) were cultured in flat-bottomed 96-well MicroWellTM plates
(NUNC, Roskilde, Denmark) at seeding densities of∼23,000 and
∼22,000 cells/well, respectively, and then cultured for 22–24 h
under standard culturing conditions (37◦C, 5% CO2, humidified
air) to reach 80–90% confluence. NIH 3T3 were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% (v/v) newborn-calf serum (NCS) (Gibco, Paisly,
UK), while HepG2 were cultured in Eagle’s minimum essential
medium (EMEM) supplemented with 10% (v/v) fetal bovine
serum (FBS, Gibco, Paisly, UK), sodium pyruvate (1mM), and
non-essential amino acids (1%, v/v). Both culturing media were
further supplemented with penicillin (100 U/mL), streptomycin
(100µg/mL), and L-glutamine (2 mM).
Effect on cell viability was determined in NIH 3T3 fibroblasts
and HepG2 hepatocytes by using the MTS/PMS assay measuring
metabolic activity. Briefly, the adhered cells were washed with
37◦C Hanks’ balanced salt solution (HBSS from Sigma-Aldrich,
St. Louis, MO, USA), containing 10mM HEPES (AppliChem,
Darmstadt, Germany), and adjusted to pH 7.4, and were then
exposed for 1 h to 100 µL of test compound(s) dissolved in
the appropriate culturing medium without serum for each cell
line. After exposure the cells were washed with HBSS containing
10mM HEPES (pH 7.4) and 100 µL of an MTS/PMS solution,
consisting of 240µg/mL MTS (Promega, Madison, WI, USA)
and 2.4µg/mL PMS (SigmaAldrich, Buchs, Switzerland) in
HBSS, was added to the cells, which then were incubated for
1 h at 37◦C with horizontal shaking under light protection.
Absorbance was measured at 492 nm by using a POLARstar
OPTIMA plate reader (BMG Labtech, Offenburg, Germany). The
relative viability was calculated according to Equation (1) with
absorbance values obtained after incubation of cells with test
compound; incubation with SDS (0.2%, w/v in medium) defined
100% cell death (Abspos), while the absorbance of cells incubated
with medium defined 0% cell death (Absneg).
Relative viability (%) =
(Abssample − Abspos)
(Absneg − Abspos)
× 100% (1)
EC50 values were calculated by using GraphPad Prism 7
(GraphPad Software, La Jolla, CA, USA) via fitting of the relative
cell viability to the concentration of the test compound by using
Equation (2):
Relative viability (%) =
Top−Bottom
1+ 10(LogIC50−Log[peptidomimetic]) ×Hill slope
(2)
With top and bottom representing the mean highest and lowest
observed values, respectively. The Hill slope represents a factor
for the steepness of the linear part of the curve. In order to
prevent erroneous calculation, the top and bottom values were
constrained to 100 and 0%, respectively. Data were collected
from technical triplicates. The selectivity index was calculated as
the average effect on cell viability (EC50 values for HepG2 and
NIH 3T3 cells) divided by the MIC.
Time-Kill Assay
Time-kill kinetic assays were performed in MDR E. coli ST131,
MDR K. pneumoniae ST258, and P. aeruginosa ATCC 27853.
Overnight cultures were subcultured in MHB II and grown to
the logarithmic phase, after which ∼106 CFU/mL cells were
transferred to 15-mL round-bottom Falcon tubes. Bacterial cells
were incubated at 37◦C with aeration in the presence or absence
of antibiotic, peptidomimetic or a combination of these at 2 ×
MIC (as observed in the growth curves; Table 6). At time points
0, 1, 2, 4, 8, and 24 h, 100 µl cells were serially diluted 10-
fold in sterile 0.9% NaCl, and then 10 µl aliquots were plated
on MHA in triplicate. The CFU/mL from each condition was
calculated from counted colonies following 18–24 h incubation
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FIGURE 1 | Structures of the α-peptide/β-peptoid hybrids listed in Table 2 and similar compounds that exhibit activity in vivo (Zaknoon et al., 2011; Czyzewski et al.,
2016, respectively).
at 37◦C. The detection limit was ∼102 CFU/mL. The CFU/mL
of each culture was graphed in GraphPad Prism 7 over time (h),
and all graphs represent the average and standard error from
two separate experiments (i.e., biological duplicates). Synergy
was defined as a ≥2-log10 CFU/mL decrease for the cultures
exposed to the antibiotic-peptidomimetic combination vs. either
compound individually. Bactericidal activity was defined as a
≥3-log10 CFU/mL decrease after 24 h incubation.
RESULTS
Identification of Two Subclasses of
Peptidomimetics That Induce
Susceptibility to Rifampicin and
Azithromycin in Gram-Negative Pathogens
Screening of peptidomimetic-antibiotic combinations was
performed in order to identify potentiators of rifampicin and
azithromycin in MDR Escherichia coli sequence type 131 (ST131)
and K. pneumoniae ST258 epidemic clones. This involved
42 selected diverse peptidomimetics that were combined at
0.5µM with each antibiotic at concentrations approximating
the clinical breakpoints in Gram-positive species (i.e., 0.5µg/mL
and 1µg/mL, for rifampicin and azithromycin, respectively)
(Clinical and Laboratory Standards Institute, 2017). Three
peptidomimetics (i.e., 1, 15, and 26) were found to inhibit
growth of both species in the presence of rifampicin, while
one compound (i.e., 1) prevented growth in combination with
azithromycin (Table 1). These peptidomimetics represent two
subclasses of α-peptide/β-peptoid hybrids: subclass I (e.g.,
1 and 15) comprising lysine-based compounds with achiral
β-peptoid phenylalanine-like residues, and subclass II (e.g.,
26) displaying both Lys and homoarginine (hArg) as cationic
residues together with α-chiral β-peptoid hydrophobic Phe-like
residues (Table 2; Figure 1). The effect on cell viability of these
three peptidomimetics was tested toward the mammalian cells
lines mouse fibroblasts (NIH 3T3) and human hepatocytes
(HepG2), which revealed that 1 and 15 exhibited promising
cell selectivity (i.e., EC50 >100µM) while peptidomimetic 26
proved to affect cell viability the most with EC50 values in
the range 50–60µM (Table 2). These peptidomimetics were
further screened for potentiation of additional 21 antibiotics
(Table 3) at sub-MIC concentrations of ≤1µM (Table 2). In
presence of peptidomimetics 1, 15, or 26, the MIC of rifampicin
(>2µg/mL) was reduced to below 1µg/mL in both MDR
E. coli and K. pneumoniae, while the MIC of erythromycin
was reduced from >4µg/mL to ≤2µg/mL in MDR E. coli,
confirming the results from the primary screening. In addition,
the MIC of clindamycin in MDR K. pneumoniae was reduced
from >4µg/mL to 2µg/mL in presence of 1µM of 26, while
the MIC of ticarcilllin/clavulanic acid in E. coli was reduced
from 64µg/mL to 16µg/mL in presence of 0.5µM of 1. Since
this E. coli strain was already susceptible to ticarcillin/clavulanic
acid, this combination was not studied further. Growth
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TABLE 3 | Potentiation of antibiotics by peptidomimetics in MDR E. coli ST131 and K. pneumoniae ST258; MICs (µg/mL) of antibiotics in presence and absence of
peptidomimetics; MICs reduced ≥4-fold in presence of a peptidomimetic are indicated in bold.
Strain K. pneumoniae ST258 E. coli ST131
Peptidomimetic 1 15 26 antibiotic alone 1 15 26 antibiotic alone
1 µM 1 µM 1 µM - 0.5 µM 0.5 µM 0.25 µM -
β-lactams
Ampicillin >16 >16 >16 >16 >16 >16 >16 >16
Penicillin >8 >8 >8 >8 >8 >8 >8 >8
Oxacillin (2% NaCl) >4 >4 >4 >4 >4 >4 >4 >4
Amoxicillin/clavulanic acid (2:1) >32 >32 >32 >32 8 8 8/4 16
Ticarcillin >64 >64 >64 >64 >64 >64 ND >64
Ticarcillin/clavulanic acid (2:1) >64 >64 >64 >64 16 32 ND 64
Cephalosporins and Carbapenems
Cefazolin >16 >16 >16 >16 >16 >16 >16 >16
Cefovecin >8 >8 >8 >8 >8 >8 >8 >8
Cefoxitin >16 >16 >16 >16 >16 4 ND 8
Cefpodoxime >16 >16 >16 >16 >16 >16 >16 >16
Ceftiofur >4 >4 >4 >4 >4 >4 ND >4
Imipenem >8 >8 >8 >8 ≤1 ≤1 ≤1 ≤1
Aminoglycosides
Amikacin 32 32 16 32 >32 8 8 16
Gentamicin ≤1 2 ≤1 2 >8 >8 >8 >8
fluoroquinolone
Enrofloxacin >2 >2 >2 >2 >2 >2 >2 >2
Marbofloxacin >2 >2 >2 >2 >2 >2 >2 >2
Miscellaneous
Chloramphenicol >16 >16 >16 >16 ≤4 ≤4 ≤4 ≤4
Clindamycin >4 >4 2 >4 4 >4 >4 >4
Doxycycline ≤2 ≤2 ≤2 4 ≤2 ≤2 ≤2 ≤2
Erythromycin >4 >4 >4 >4 1 2 2 >4
Rifampicin ≤1 ≤1 ≤1 >2 ≤1 ≤1 ≤1 >2
Trimethoprim/sulfamethoxazole >38 >38 >38 >38 >38 >38 >38 >38
Peptidomimetic MICs are reported in Table 2 and as follows: 16, 32, 8, 2, 1 and 1µM, respective to the order listed in Table 3.
inhibition occurred at concentrations ≥4-fold below the MICs
of the peptidomimetic (except for 15 in E. coli) and antibiotic
alone, indicating that the combinations exerted synergistic
effects. Synergy was confirmed by the checkerboard assay, and
fractional inhibitory concentration indexes (FICIs) ranged
from 0.05 to 0.38 (Table 4). With FICIs ranging from 0.05 to
0.07, the synergistic peptidomimetic-rifampicin interactions
in K. pneumoniae were especially potent. The peptidomimetic
26-clindamycin synergistic interaction in K. pneumoniae was
also potent, however, due to the relatively high effect of 26
on the viability of eukaryotic cells, this combination was not
studied further.
To explore additional compounds within the two identified
subclasses of peptidomimetics, found to enhance the antibacterial
effect of rifampicin and azithromycin, the study was extended
to include three additional peptidomimetics, 14 and 25,
28 (also belonging to subclasses I or II; Table 2). These
three peptidomimetics also exhibited an ability to potentiate
rifampicin and azithromycin in MDR E. coli and K. pneumoniae
(Table 4). Overall, the degree of synergy was similar to that
seen for combinations containing 1, 15, and 26, resulting in
potentiation of rifampicin and azithromycin (to reach MICs
of ≤1 and ≤8µg/mL, respectively) in both species. Similar
to the subclass I compounds (i.e., 1 and 15), peptidomimetic
14 displayed the lowest effect on cell viability with EC50
values of 323µM and 234µM in NIH 3T3 and HepG2,
respectively (Table 2). In contrast, peptidomimetic 25 had a
noticeably higher effect on cell viability with EC50 values in
the range 80–170µM, although somewhat less toxic than the
highly cationic peptidomimetic 26. Among, the subclass II
compounds, peptidomimetic 28 had the least effect on cell
viability (EC50 >100µM). Overall, the HepG2 liver cell line was
more sensitive to the peptidomimetics than the fibroblast cells
(i.e., NIH 3T3).
We extended our study to species outside Enterobacteriaceae
by including a reference strain of P. aeruginosa, which displayed
a susceptibility pattern similar to that found for E. coli (Table 2).
Similarly, synergy was observed with FICIs ranging from
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TABLE 4 | Interaction of azithromycin (AZM) and rifampicin (RIF) with peptidomimetics in E. coli ST131, K. pneumoniae ST258, and P. aeruginosa as determined in the
checkerboard assay.
Species Antibiotic (µg/mL) Peptidomimetic (µM) FICI
Agent MIC alone MIC in combination Compound no. MIC alone MIC in combination
(Selectivity index)
E. coli ST131
AZM 8 1 1 2 0.25 (669) 0.25
1 14 4 0.25 (1114) 0.19
1 15 1 0.13 (1352) 0.25
0.5 25 2 0.25 (504) 0.19
1 26 1 0.25 (226) 0.38
0.5 28 2 0.5 (336) 0.31
RIF 4 0.06 1 2 0.5 (335) 0.27
0.25 14 4 0.25 (1114) 0.13
0.5 15 1 0.13 (1352) 0.25
0.5 25 2 0.25 (504) 0.25
0.5 26 1 0.25 (226) 0.38
0.13 28 2 0.5 (336) 0.28
K. pneumoniae ST258
AZM 32 4 1 16 0.5 (335) 0.16
4 14 64 2 (139) 0.16
8 15 32 0.5 (338) 0.27
8 25 8 0.5 (252) 0.31
8 26 8 0.5 (113) 0.31
4 28 16 2 (84) 0.25
RIF 16 0.25 1 16 0.5 (335) 0.05
1 14 64 1 (279) 0.08
0.5 15 32 0.5 (338) 0.05
0.06 25 8 1 (126) 0.13
0.06 26 8 0.5 (113) 0.07
0.5 28 16 1 (168) 0.09
CLI 125 4 26 8 0.5 (113) 0.09
P. aeruginosa ATCC 27853
AZM >128 8 1 1 0.25 (669) 0.28
1 14 16 4 (70) 0.25
2 15 1 0.5 (338) 0.51
4 25 8 1 (126) 0.14
0.5 26 2 1 (56) 0.50
0.5 28 16 2 (84) 0.13
RIF 32 1 1 1 0.25 (669) 0.28
1 14 16 4 (70) 0.28
0.5 15 1 0.5 (338) 0.52
0.06 25 8 1 (126) 0.13
0.06 26 2 0.5 (113) 0.25
0.06 28 16 4 (42) 0.25
Compound numbers are stated in bold.
0.13 to 0.5, except for combinations with peptidomimetic
15, which only displayed a slight potentiation of antibiotic
activity (i.e., FICIs >0.5; Table 4). In the presence of sub-
MIC concentrations of peptidomimetics 1, 14, 15, 25,
26, or 28, the MICs of azithromycin were reduced 32- to
512-fold, corresponding to MIC values within the range
0.5-8µg/mL in the synergistic combinations (Table 4).
However, the most pronounced enhancement of antibiotic
potency was observed when the peptidomimetics were
used in combination treatment of K. pneumoniae, since
the peptidomimetics in this case could be applied in 8- to
64-fold lower concentrations than their MICs as compared
to only 2- to 16-fold lower than their MICs in E. coli
and P. aeruginosa.
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As a preliminary investigation of the therapeutic potential of
the present subclasses of peptidomimetic antibiotic adjuvants,
their cell selectivity was estimated as a measure that reflects
both antibacterial activity and effect on viability of mammalian
cells. Typically, a cell selectivity index (SI) is calculated as
the ratio between the averaged EC50 values and the MIC of
the peptidomimetic in each bacterial species. Peptidomimetics
1 and 15, belonging to subclass I, proved to be the most
selective against E. coli and P. aeruginosa over mammalian cells
with SIs within the range 84–169 (Table 2). When targeting
MDR K. pneumoniae all compounds displayed poor selectivity,
with 25 having a modest SI of 16. As the MICs of the
peptidomimetics in combination with antibiotics were lower,
the SIs of the combinations with azithromycin or rifampicin
were improved, assuming a negligible contribution from the
antibiotics to the negative effects on mammalian cell viability,
since these were employed in clinically relevant concentrations
(Baker et al., 2018). Toward E. coli, the most favorable
combinations, containing peptidomimetics 14 and 15, would
have approximated SIs >1,000 (Table 4). However, these two
peptidomimetics were less selective against K. pneumoniae and
P. aeruginosa with SIs within the range 70–338. While 14 had
the highest EC50 (Table 2), the concentration of 14 required
in synergistic combinations were ≥1µM and 4µM, in K.
pneumoniae and P. aeruginosa, respectively, (Table 4). Likewise,
compound 15 did not display synergy with any of the antibiotics
in P. aeruginosa (Table 4). In contrast, peptidomimetic 1
exhibited synergy with both rifampicin and azithromycin at
submicromolar concentrations with estimated SIs ≥335 against
all three species (Table 4). With an average EC50 >150µM,
peptidomimetic 1 was also considered relatively non-toxic in
itself. In addition, peptidomimetic 1 was the only compound
that exhibited synergy at submicromolar concentrations in
combination with antibiotics at clinically relevant concentrations
in all three species, and thus this compound was selected for
further studies.
Bacterial Growth and Killing in Presence of
Peptidomimetic 1-Antibiotic Combinations
To ascertain that susceptibility of clinical isolates of
Enterobacteriaceae and P. aeruginosa to combinations of
peptidomimetic 1 with rifampicin or azithromycin could
be induced, the combinations were tested with respect to
MIC against several MDR isolates of each species. Overall,
peptidomimetic 1 (at ≤1µM) induced susceptibility to
rifampicin and azithromycin in 83% of the isolates (i.e., in 30
of 36 isolates; Table 5). Notably, most E. coli isolates proved
susceptible to 0.25–0.5µg/mL rifampicin and 2–4µg/mL
azithromycin in combination with 0.5–1µM peptidomimetic 1.
While submicromolar concentrations of 1 in the majority of K.
pneumoniae isolates were sufficient to induce susceptibility
to rifampicin and azithromycin, three isolates required
considerably higher concentrations of 1 (i.e., 2–8µM). By
contrast P. aeruginosa isolates typically required 1–8µM of 1 to
reduce the MIC of rifampicin and azithromycin to 0.5µg/mL
and 4–8µg/mL, respectively.
TABLE 5 | MICs of Peptidomimetic (PM) 1-rifampicin and PM 1-azithromycin
combinations in E. coli, K. pneumoniae, and P. aeruginosa clinical isolates and
reference strains.
PM 1 / Rifampicin PM 1/ Azithromycin
Species MIC (µM/µg mL−1) MIC (µM/µg mL−1)
E. coli Isolates
1 0.5/0.25 0.5/2
2 1/0.5 0.5/2
3 0.5/0.25 0.5/2
4 0.5/0.25 1/4
5 0.5/0.25 1/4
6 1/0.5 1/4
7 0.5/0.25 1/4
8 0.5/0.25 1/4
9 0.5/0.25 0.5/2
10 0.5/0.25 0.5/2
ST131 0.5/0.25 1/4
ATCC 25922 0.5/0.25 0.5/2
K. pneumoniae Isolates
1 0.5/0.25 >4/16
2 8/4 0.5/2
3 0.5/0.25 0.5/2
4 1/0.5 0.5/2
5 0.5/0.25 1/4
6 2/1 0.5/2
7 1/0.5 0.5/2
8 0.5/0.25 0.5/2
9 0.5/0.25 0.5/2
10 4/2 >4/16
ST258 0.5/0.25 4/16
ATCC 13883 0.5/0.25 0.5/2
P. aeruginosa Isolates
1 1/0.5 1/4
2 1/0.5 2/8
3 1/0.5 1/4
4 1/0.5 2/8
5 0.5/0.25 1/4
6 1/0.5 1/4
7 1/0.5 1/4
8 1/0.5 0.5/2
9 1/0.5 1/4
10 4/2 1/4
11 8/4 >4/16
ATCC 27853 0.5/0.25 1/4
To understand the dynamics of the interaction of
peptidomimetic 1 with antibiotics, the kinetics of bacterial
growth and killing were investigated by growth-curve and
time-kill assays. All combinations exhibited synergistic growth
inhibition or bactericidal activity in growth-curve and time-kill
assays. The growth curves of the combinations corresponded well
to the MICs (Table 6) found in static growth assays (Tables 4, 5).
In the time-kill assays, the concentrations of tested compounds
were 2-fold above the MIC observed in the growth-curve assays,
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TABLE 6 | MIC and MBC of peptidomimetic (PM) 1 (µM), azithromycin (AZM) and rifampicin (RIF) (µg/mL) and combinations (peptidomimetic + antibiotic) as determined
in the growth-curve assay.
E. coli ST131 K. pneumoniae ST258 P. aeruginosa ATTC 27853
Agent MIC MBC MIC MBC MIC MBC
AZM 8 >16 >32 >32 >128 >128
PM1 + AZM 0.25 + 1 0.5 + 2 0.5 + 4 4 + 32 0.25 + 8 0.5 + 16
RIF >4 >4 >16 >16 >64 >64
PM1 + RIF 0.25 + 0.31 0.25 + 0.31 0.25 + 0.125 0.25 + 0.125 0.5 + 1 1 + 2
PM1 1 1 8 16–32 1 2
since a 2-fold higher bacterial concentration was used. The tested
peptidomimetic 1-rifampicin combinations were bactericidal
in all three species, as at least a 3-log reduction in CFU/mL
was reached within the initial 4 h of exposure (Figures 3A–C).
Similarly, peptidomimetic 1-azithromycin combinations
(Figures 3D,F) were bactericidal in E. coli and P. aeruginosa.
However, in K. pneumoniae (Figure 3E), the combination was
bacteriostatic as it only reduced the initial inoculum CFU by
∼1.5 log, also reflecting the high MBC, measured at the end
of the growth-curve assay (Table 6). Although the MBCs of
combinations in P. aeruginosa were only 2-fold higher than
the MIC (Table 6), in the time-kill assay this species started to
recover after 4 h of exposure to the rifampin- and azithromycin-
peptidomimetic 1 combinations (Figures 3C,F). A similar,
but less pronounced, trend was observed for the 1-rifampicin
combination in E. coli, for which the CFU concentration had
increased at the 24 h time point (Figure 3A). In addition,
reduced growth was seen for E. coli and P. aeruginosa in the
presence of 1 alone (at concentrations 2-fold below the MIC)
within the first 4 h of exposure (Figures 3A,C,D).
DISCUSSION
In the present study an array of peptidomimetics was screened in
order to identify possible potentiators of antibiotics against MDR
Gram-negative pathogens. In particular, the aimwas to repurpose
antibiotics typically used against Gram-positive pathogens. This
enabled identification of a lead compound, peptidomimetic
1, which exhibited high cell selectivity and displayed synergy
with rifampicin and azithromycin at submicromolar, sub-MIC
concentrations. Moreover, this compound was found capable
of inducing susceptibility to antibiotics in MDR strains and
clinical isolates of E. coli, K. pneumoniae and P. aeruginosa.
Initial characterization of five additional peptidomimetics with
similar structural composition also revealed potent antibacterial
synergy with rifampicin and azithromycin, suggesting that the
α-peptide/β-peptoid backbone constitutes a promising template
for design of potentiators of antibiotics that Gram-negative
pathogens are intrinsically resistant to.
The structural features of the peptidomimetics, identified as
antibiotic adjuvants, have been examined in previous studies,
focusing on the structure-activity relationships as potential
directly antimicrobial agents (Jahnsen et al., 2014; Molchanova
et al., 2017b); yet the present work constitutes the first report
on their potential for synergy with traditional antibiotics. While
the effect of human serum albumin and plasma on the antibiotic
adjuvant activity was not addressed in this study, we have in
previous work found that the antibacterial activity of similar
peptidomimetics (belonging to the same peptidomimetic class)
is independent of the presence of physiological concentration
human serum albumin, while test in 25% plasma in fact
increased their antimicrobial potency (Hein-Kristensen et al.,
2013; Citterio et al., 2016). Likewise, the mechanism of synergy
has not been investigated in the present study, but this type
of peptidomimetics was previously found to exhibit bactericidal
activity via membrane permeabilization (Hein-Kristensen et al.,
2011), suggesting that at low concentrations these compounds
may cause non-lethal membrane alterations that facilitate
enhanced influx of antibiotics. The transient growth inhibition
induced by these compounds at sub-MIC concentrations in
growth-curve and time-kill assays (Figures 2, 3) supports this
hypothesis. The six studied peptidomimetics range in length
from 12 to 16 residues and display N-terminal end groups
(Table 2; Figure 1). Subclass I peptidomimetics display a 1:1 ratio
of alternating Lys residues and βNPhe peptoid units as well
as either no end group or an acetyl group at the N-terminus
(Table 1). Compound 1 had previously been found to be active
against the Gram-negative E. coli, P. aeruginosa, Acinetobacter
baumannii and Salmonella Typhimurium as well as the Gram-
positive Staphylococcus pseudintermedius (Molchanova et al.,
2017b), while 15 had proved antibacterial against E. coli (Jahnsen
et al., 2012). Interestingly, compound 14 at 1µM has been
shown to block the pro-inflammatory effect of LPS (Skovbakke
et al., 2015), thereby implying that LPS released from lysed
bacteria might constitute a less critical issue when applying this
compound as an antibiotic adjuvant.
In accordance with the high structural similarity between 1
and 15, these analogs exhibited almost equipotent antibacterial,
cytotoxic activity and potentiation of antibiotics (Tables 2,
4). Nonetheless, 1 appeared to exert slightly more efficient
potentiation of antibiotics in P. aeruginosa. In contrast, 14
is four residues shorter than 15, and hence exhibited a less
pronounced effect on the viability of mammalian cells, since
this effect is strongly dependent on oligomer length (Jahnsen
et al., 2014). Nonetheless, shortening of oligomer length gives
rise to a concomitantly lower antibacterial activity, as also
seen in the MDR strains of K. pneumoniae and P. aeruginosa
(Table 2), yet 14 retained a similar degree of synergy with
antibiotics (Table 4). Consequently, the selectivity indexes for
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FIGURE 2 | Peptidomimetic 1 potentiates activity of azithromycin and rifampicin in growth-curve assays (A–F). Growth of E. coli ST131 (A,D), K. pneumoniae ST258
(B,E) and P. aeruginosa ATCC 27853 (C,F) in absence or presence of antibiotic, peptidomimetic (PM) 1 or their combinations were recorded at regular intervals by
measuring the optical density (OD) of each culture at 600 nm, and then these data were graphed over time (h). Initial bacterial concentration was ∼5 × 105 CFU/mL.
The MIC values of each compound are listed in Table 6.
14 in combination with rifampicin or azithromycin in E. coli
proved to be themost favorable among all of the peptidomimetic-
antibiotic combinations tested. However, due to the typically 2- to
8-fold higher concentrations of 14 in synergistic combinations,
these gave rise to less pronounced selectivity for K. pneumoniae
and P. aeruginosa over mammalian cells (as reflected in its SIs;
Table 2). While subclass I and II peptidomimetics share the
same α-peptide/β-peptoid hybrid backbone structure, subclass
II is characterized by a mixed Lys and hArg content (in a
1:1 ratio) of cationic residues (Table 2). The increased effect
of subclass II peptidomimetics 25 and 26 on the viability of
mammalian cell lines may be correlated to the presence of hArg
residues displaying guanidinium functionalities, which confer
an increased propensity to interact with, and thereby disrupt,
mammalian membranes (Chan et al., 2006; Hein-Kristensen
et al., 2011; Findlay et al., 2012; Jahnsen et al., 2014). However,
even though 28 belongs to subclass II it had a similarly low
effect on mammalian cell viability as that of compounds 1 and
15, which may be explained by its modification with a polar
PEG-like moiety (i.e., 3,6,9-trioxadecanoyl; TODA) instead of a
cationic moiety containing amine functionalities (i.e., NDab or
spermine-acetyl moiety present in 25 and 26, respectively). Thus,
the increased effect of 25 and 26 on mammalian cell viability
may be due to their increased net cationic charge (Jahnsen
et al., 2015). Moreover, while 28 retained antibacterial potency
similar to its parent unmodified compound, it had a lower effect
on mammalian cell viability than the parent compound (for
NIH 3T3: EC50 ∼218µM vs. 117µM) (Jahnsen et al., 2015),
suggesting that introduction of the TODA moiety is beneficial
with respect to therapeutic utility.
Interestingly, nine compounds in the peptidomimetic array
contained the subclass II core structure, yet only four compounds
were detected as potentiators of antibiotics. Another shorter
peptidomimetic (i.e., 10) also potentiated rifampicin activity (but
not that of azithromycin) in MDR E. coli. In contrast, the other
five compounds (i.e., 9, 12, 13, 27, and 29) did not exhibit
any potentiation activity, detectable at the low concentrations
tested in the screening (Table 1). This suggests that addition of
a palmitoyl moiety (in 9, 12, 13), a cinnamoyl moiety (in 27), a
fluorinated phenylalanine (in 29), or shorter oligomers (i.e., 9 and
13) may result in lowered potency or abolish potentiation, while
similar modifications (e.g., in 29) did not alter the antibacterial
activity (Jahnsen et al., 2015). Based on these observations, there
appears to be distinct physicochemical and/or overall structural
requirements for achieving efficient potentiation of antibiotics
and high direct antibacterial activity, respectively.
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FIGURE 3 | Peptidomimetic 1-combinations enhance bactericidal activity (A–F). Time-kill kinetics for E. coli ST131 (A,D), K. pneumoniae ST258 (B,E) and P.
aeruginosa ATTC 27853 (C,F) exposed to peptidomimetic (PM) 1, azithromycin (AZM), rifampicin (RIF), peptidomimetic-antibiotic combinations or without treatment
(controls); CFU/mL data are graphed at time points 0, 1, 2, 4, 8, and 24 h of exposure. Initial bacterial concentration was ∼106 CFU/mL. The MBC values of each
compound are listed in Table 6.
The present results infer that peptidomimetic 1 has a potential
for repurposing rifampicin and azithromycin for treatment of
MDR Gram-negative infections. While this peptidomimetic was
considered to be the most promising due to its low toxicity
(with ensuing favorable cell selectivity) and ability to exert
synergy with antibiotics at submicromolar levels in all three
species, the additional peptidomimetics with low effect on
mammalian cell viability, characterized in this study, may also
merit further investigation. Since a prerequisite for successful
combination therapy is that the effective concentrations of
both peptidomimetic and antibiotic can be achieved at
the infection site, it is critical that future studies address
in vivo pharmacokinetic/pharmacodynamics and acute toxicity
to assess the clinical potential of such peptidomimetic-antibiotic
combinations. In particular, co-formulation of antibiotic and
peptidomimetics as nanoparticles would be preferable to ensure
in vivo co-localization of the compounds in the appropriate
ratios (Carmona-Ribeiro and de Melo Carrasco, 2014; Liu
et al., 2016; Nordström and Malmsten, 2017). While in vivo
data currently are lacking for the α-peptide/β-peptoid hybrids
described in the present study, peptidomimetics (including
the 12-mer, H-(NLys-Nspe-Nspe)4-NH2 and the pentamer
C12K-2α8) displaying similar structural features such as a
high content of both cationic and hydrophobic residues
(aromatic or aliphatic) have previously been found to exhibit
in vivo activity (antibacterial and antiparasitic, respectively)
(Zaknoon et al., 2011; Czyzewski et al., 2016). Based on
overall structural similarity, the peptidomimetics identified in
the present study appear likely to possess physicochemical
properties compatible with in vivo activity. Moreover, clinical
breakpoints for rifampicin and azithromycin may be used to
estimate the therapeutic potential of the antibiotics in these
drug combinations. Although no clinical breakpoint points
are available for these antibiotics in Enterobacteriaceae or P.
aeruginosa, bactericidal efficacy of the 1-rifampicin combination
occurred at concentrations ranging from 0.06 to 2µg/mL
in time-kill assays, which is below the resistance breakpoint
for rifampicin alone in Staphylococcus species (R ≥4µg/mL)
(Clinical and Laboratory Standards Institute, 2017). Similarly,
at concentrations below the azithromycin resistance breakpoint
for Salmonella typhi (R ≥32µg/mL), the 1-azithromycin
combination exerted growth-inhibitory and bactericidal activity.
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Recent studies also indicate that antibacterial efficacy of
azithromycin therapy against Gram-negative pathogens in vivo is
considerably higher than implied by in vitro susceptibility testing
in standard MHB media (Lin et al., 2015; Ersoy et al., 2017).
Importantly, low concentrations (≤ 1µM) of peptidomimetic 1
were able to induce susceptibility to azithromycin and rifampicin
in most of the clinical isolates tested. Thus the low effect of 1 on
viability of mammalian cells and its high potency in combination
with antibiotics may facilitate circumvention of pharmacological
obstacles frequently associated with antimicrobial peptides and
peptidomimetics (Molchanova et al., 2017a).
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